Tonix Net Invested Capital vs Net Receivables Analysis

TNXP Stock

USD 0.16 0.01 5.88%

Tonix Pharmaceuticals financial indicator trend analysis is much more than just breaking down Tonix Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tonix Pharmaceuticals is a good investment. Please check the relationship between Tonix Pharmaceuticals Net Invested Capital and its Net Receivables accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tonix Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

Net Invested Capital vs Net Receivables

Net Invested Capital vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tonix Pharmaceuticals Net Invested Capital account and Net Receivables. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Tonix Pharmaceuticals' Net Invested Capital and Net Receivables is 0.85. Overlapping area represents the amount of variation of Net Invested Capital that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Tonix Pharmaceuticals Holding, assuming nothing else is changed. The correlation between historical values of Tonix Pharmaceuticals' Net Invested Capital and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Invested Capital of Tonix Pharmaceuticals Holding are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Net Invested Capital i.e., Tonix Pharmaceuticals' Net Invested Capital and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.85

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Net Receivables

Most indicators from Tonix Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tonix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tonix Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

At this time, Tonix Pharmaceuticals' Selling General Administrative is relatively stable compared to the past year. As of 06/01/2024, Enterprise Value Over EBITDA is likely to grow to 0.08, while Enterprise Value is likely to drop (8.7 M).

	2021	2022	2023	2024 (projected)
Total Operating Expenses	92.3M	112.1M	117.1M	123.0M
Cost Of Revenue	92.3M	112.1M	9.0M	8.6M

Total Operating Expenses Cost Of Revenue

Tonix Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Accounts Payable	Short Long Term Debt Total	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt
Total Assets		0.83	0.96	0.94	-0.8	-0.84	0.86	0.85	0.82	0.92	0.59	0.23	0.92	0.73	0.89	0.69	0.88	0.42	0.89	0.94	0.86	0.69	0.84	0.11	0.57	0.68
Other Current Liab	0.83		0.92	0.62	-0.34	-0.94	0.44	0.43	0.57	0.96	0.93	0.14	0.94	0.97	0.5	0.33	0.51	0.82	0.89	0.96	0.97	0.61	0.98	0.07	0.2	0.69
Total Current Liabilities	0.96	0.92		0.85	-0.66	-0.91	0.73	0.73	0.76	0.97	0.73	0.27	0.96	0.86	0.78	0.63	0.81	0.59	0.93	0.98	0.91	0.68	0.9	0.15	0.5	0.74
Total Stockholder Equity	0.94	0.62	0.85		-0.92	-0.68	0.94	0.94	0.85	0.77	0.33	0.25	0.77	0.49	0.96	0.75	0.94	0.14	0.76	0.8	0.69	0.7	0.65	0.08	0.64	0.56
Net Debt	-0.8	-0.34	-0.66	-0.92		0.42	-0.99	-0.99	-0.78	-0.54	0.0	-0.17	-0.55	-0.2	-0.98	-0.86	-0.94	0.16	-0.57	-0.57	-0.4	-0.55	-0.36	0.01	-0.78	-0.42
Retained Earnings	-0.84	-0.94	-0.91	-0.68	0.42		-0.5	-0.49	-0.55	-0.92	-0.85	-0.27	-0.99	-0.91	-0.56	-0.36	-0.58	-0.72	-0.92	-0.94	-0.92	-0.51	-0.93	-0.21	-0.21	-0.82
Cash	0.86	0.44	0.73	0.94	-0.99	-0.5		0.99	0.81	0.62	0.11	0.17	0.63	0.31	0.99	0.87	0.96	-0.05	0.65	0.65	0.49	0.58	0.45	0.01	0.78	0.48
Cash And Short Term Investments	0.85	0.43	0.73	0.94	-0.99	-0.49	0.99		0.8	0.61	0.1	0.27	0.62	0.3	0.99	0.86	0.96	-0.07	0.63	0.65	0.47	0.59	0.43	0.02	0.78	0.45
Net Receivables	0.82	0.57	0.76	0.85	-0.78	-0.55	0.81	0.8		0.71	0.3	0.12	0.64	0.45	0.83	0.71	0.8	0.16	0.76	0.69	0.59	0.79	0.56	0.04	0.48	0.5
Common Stock Total Equity	0.92	0.96	0.97	0.77	-0.54	-0.92	0.62	0.61	0.71		0.83	0.11	0.95	0.91	0.66	0.53	0.69	0.71	0.94	0.99	0.97	0.63	0.96	0.18	0.39	0.73
Common Stock Shares Outstanding	0.59	0.93	0.73	0.33	0.0	-0.85	0.11	0.1	0.3	0.83		0.06	0.8	0.97	0.17	0.06	0.2	0.96	0.75	0.82	0.89	0.39	0.91	0.13	-0.04	0.6
Short Term Investments	0.23	0.14	0.27	0.25	-0.17	-0.27	0.17	0.27	0.12	0.11	0.06		0.26	0.15	0.29	0.09	0.28	-0.02	0.15	0.2	0.1	0.22	0.1	0.26	0.07	0.11
Other Stockholder Equity	0.92	0.94	0.96	0.77	-0.55	-0.99	0.63	0.62	0.64	0.95	0.8	0.26		0.89	0.67	0.46	0.68	0.65	0.95	0.97	0.94	0.57	0.93	0.19	0.32	0.8
Total Liab	0.73	0.97	0.86	0.49	-0.2	-0.91	0.31	0.3	0.45	0.91	0.97	0.15	0.89		0.37	0.29	0.41	0.91	0.85	0.91	0.91	0.49	0.93	0.14	0.18	0.68
Total Current Assets	0.89	0.5	0.78	0.96	-0.98	-0.56	0.99	0.99	0.83	0.66	0.17	0.29	0.67	0.37		0.86	0.97	0.0	0.68	0.7	0.53	0.63	0.49	0.04	0.76	0.5
Common Stock	0.69	0.33	0.63	0.75	-0.86	-0.36	0.87	0.86	0.71	0.53	0.06	0.09	0.46	0.29	0.86		0.88	0.02	0.57	0.54	0.31	0.45	0.29	0.13	0.92	0.43
Accounts Payable	0.88	0.51	0.81	0.94	-0.94	-0.58	0.96	0.96	0.8	0.69	0.2	0.28	0.68	0.41	0.97	0.88		0.05	0.69	0.71	0.55	0.61	0.52	0.13	0.81	0.56
Short Long Term Debt Total	0.42	0.82	0.59	0.14	0.16	-0.72	-0.05	-0.07	0.16	0.71	0.96	-0.02	0.65	0.91	0.0	0.02	0.05		0.64	0.69	0.75	0.2	0.78	0.14	-0.08	0.53
Other Liab	0.89	0.89	0.93	0.76	-0.57	-0.92	0.65	0.63	0.76	0.94	0.75	0.15	0.95	0.85	0.68	0.57	0.69	0.64		0.93	0.87	0.58	0.87	0.21	0.35	0.86
Net Tangible Assets	0.94	0.96	0.98	0.8	-0.57	-0.94	0.65	0.65	0.69	0.99	0.82	0.2	0.97	0.91	0.7	0.54	0.71	0.69	0.93		0.96	0.64	0.95	0.12	0.41	0.72
Property Plant And Equipment Net	0.86	0.97	0.91	0.69	-0.4	-0.92	0.49	0.47	0.59	0.97	0.89	0.1	0.94	0.91	0.53	0.31	0.55	0.75	0.87	0.96		0.58	1.0	0.16	0.2	0.69
Current Deferred Revenue	0.69	0.61	0.68	0.7	-0.55	-0.51	0.58	0.59	0.79	0.63	0.39	0.22	0.57	0.49	0.63	0.45	0.61	0.2	0.58	0.64	0.58		0.57	-0.16	0.31	0.27
Non Current Assets Total	0.84	0.98	0.9	0.65	-0.36	-0.93	0.45	0.43	0.56	0.96	0.91	0.1	0.93	0.93	0.49	0.29	0.52	0.78	0.87	0.95	1.0	0.57		0.16	0.18	0.69
Non Currrent Assets Other	0.11	0.07	0.15	0.08	0.01	-0.21	0.01	0.02	0.04	0.18	0.13	0.26	0.19	0.14	0.04	0.13	0.13	0.14	0.21	0.12	0.16	-0.16	0.16		0.07	0.28
Other Assets	0.57	0.2	0.5	0.64	-0.78	-0.21	0.78	0.78	0.48	0.39	-0.04	0.07	0.32	0.18	0.76	0.92	0.81	-0.08	0.35	0.41	0.2	0.31	0.18	0.07		0.26
Long Term Debt	0.68	0.69	0.74	0.56	-0.42	-0.82	0.48	0.45	0.5	0.73	0.6	0.11	0.8	0.68	0.5	0.43	0.56	0.53	0.86	0.72	0.69	0.27	0.69	0.28	0.26

Click cells to compare fundamentals

Tonix Pharmaceuticals Account Relationship Matchups

Tonix Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.6M	98.2M	240.9M	225.7M	154.5M	162.2M
Other Current Liab	1.0M	2.5M	5.1M	6.4M	9.5M	10.0M
Total Current Liabilities	5.1M	9.8M	21.7M	18.2M	18.9M	19.8M
Total Stockholder Equity	9.4M	87.6M	218.7M	207.2M	105.5M	53.9M
Net Debt	(10.9M)	(75.8M)	(177.7M)	(119.5M)	(15.1M)	(15.9M)
Retained Earnings	(217.1M)	(267.5M)	(359.8M)	(470.0M)	(600.7M)	(570.6M)
Cash	11.2M	77.1M	178.7M	120.2M	24.9M	37.7M
Cash And Short Term Investments	11.2M	77.1M	178.7M	120.2M	24.9M	39.9M
Net Receivables	1.0M	7.6M	7.7M	8.0M	4.6M	3.7M
Common Stock Total Equity	3K	9K	206K	496K	570.4K	598.9K
Common Stock Shares Outstanding	8.0K	473.0K	1.8M	5.7M	17.0M	17.9M
Liabilities And Stockholders Equity	14.6M	98.2M	240.9M	225.7M	154.5M	162.2M
Other Stockholder Equity	226.5M	355.0M	578.1M	677.3M	706.4M	741.7M
Total Liab	5.1M	10.5M	22.2M	18.5M	48.9M	51.4M
Total Current Assets	13.9M	88.0M	189.0M	130.8M	47.8M	44.4M
Common Stock	9K	206K	496K	76K	59.0K	67.6K
Accounts Payable	3.1M	4.6M	13.3M	8.1M	3.8M	3.2M
Net Tangible Assets	9.3M	87.5M	218.7M	207.2M	238.3M	250.2M
Property Plant And Equipment Net	390K	9.8M	51.5M	94.5M	94.9M	99.6M
Current Deferred Revenue	704K	2.2M	2.8M	3.3M	3.0M	1.7M
Non Current Assets Total	610K	10.2M	51.9M	94.9M	106.7M	112.0M
Retained Earnings Total Equity	(188.5M)	(217.1M)	(267.5M)	(359.8M)	(323.8M)	(307.6M)
Non Current Liabilities Total	6K	716K	467K	328K	30.0M	31.6M
Capital Surpluse	212.2M	226.5M	355.0M	578.1M	664.9M	698.1M
Other Current Assets	2.7M	10.9M	10.4M	10.5M	4.1M	3.6M
Property Plant And Equipment Gross	390K	9.8M	51.9M	96.2M	100.2M	105.2M
Accumulated Other Comprehensive Income	(46K)	(62K)	(92K)	(167K)	(232K)	(220.4K)
Property Plant Equipment	34K	9.8M	51.5M	94.5M	108.7M	114.1M
Net Invested Capital	9.4M	87.6M	218.7M	207.2M	112.1M	107.4M
Net Working Capital	8.8M	78.2M	167.3M	112.6M	28.9M	27.4M
Capital Stock	9K	206K	496K	76K	59K	56.1K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Tonix Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Tonix Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Tonix Pharmaceuticals Holding Stock. Highlighted below are key reports to facilitate an investment decision about Tonix Pharmaceuticals Holding Stock:

How To Invest In Tonix

Details

Is Tonix Stock a good investment?

Details

What is Tonix Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tonix Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Tonix Stock analysis

When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	CEOs Directory Screen CEOs from public companies around the world
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope

Is Tonix Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tonix Pharmaceuticals. If investors know Tonix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tonix Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.82)

Revenue Per Share

0.295

Return On Assets

(0.42)

Return On Equity

(0.72)

The market value of Tonix Pharmaceuticals is measured differently than its book value, which is the value of Tonix that is recorded on the company's balance sheet. Investors also form their own opinion of Tonix Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Tonix Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tonix Pharmaceuticals' market value can be influenced by many factors that don't directly affect Tonix Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tonix Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tonix Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tonix Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tonix Net Invested Capital vs Net Receivables Analysis

Net Invested Capital vs Net Receivables

Net Invested Capital vs Net Receivables Correlation Analysis

Correlation Coefficient

Net Invested Capital

Net Receivables

Tonix Pharmaceuticals fundamental ratios Correlations

Tonix Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tonix Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Tonix Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments
Net Tangible Assets	+ 0.99	Common Stock Total Equity
Non Current Assets Total	+ 0.98	Other Current Liab

Other Stockholder Equity	- 0.99	Retained Earnings
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Current Assets	- 0.98	Net Debt
Net Tangible Assets	- 0.94	Retained Earnings
Accounts Payable	- 0.94	Net Debt